Try

Edgewise Therapeutics, Inc.

EWTXUnited States

22 filed reports · 200 financial concepts · 0 earnings calls · 0 media appearances

Filed reports

22 reports · Mar 2021 to Jun 2026

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR171,696Mar 2021 to Jun 2026
Annual · 10-KSEC EDGAR51,191Dec 2021 to Dec 2025

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q210-QJun 30, 2026Aug 6, 2026218Open
FY2026 Q110-QMar 31, 2026May 7, 2026125Open
FY202510-KDec 31, 2025Feb 26, 2026487Open
FY2025 Q310-QSep 30, 2025Nov 6, 2025154Open
FY2025 Q210-QJun 30, 2025Aug 7, 202591Open
FY2025 Q110-QMar 31, 2025May 8, 202591Open
FY202410-KDec 31, 2024Mar 3, 2025136Open
FY2024 Q310-QSep 30, 2024Nov 7, 202499Open
FY2024 Q210-QJun 30, 2024Aug 8, 202481Open
FY2024 Q110-QMar 31, 2024May 9, 202480Open
FY202310-KDec 31, 2023Feb 22, 2024201Open
FY2023 Q310-QSep 30, 2023Nov 9, 202399Open

Financial data

200 concepts · 2,887 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial190 concepts · 2,780 facts · Dec 2019 to Jul 2026

  • Adjustments to additional paid in capital share based compensation stock options requisite service period recognition32 · Mar 2020 to Jun 2026
  • Allocated share based compensation expense32 · Mar 2020 to Jun 2026
  • Cash and cash equivalents at carrying value32 · Mar 2020 to Jun 2026
  • Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect32 · Mar 2020 to Jun 2026
  • Comprehensive income net of tax32 · Mar 2020 to Jun 2026
  • Depreciation32 · Mar 2020 to Jun 2026
  • General and administrative expense (US GAAP)32 · Mar 2020 to Jun 2026
  • Increase decrease in accounts payable32 · Mar 2020 to Jun 2026
  • Increase decrease in employee related liabilities32 · Mar 2020 to Jun 2026
  • Increase decrease in other accrued liabilities32 · Mar 2020 to Jun 2026
  • Increase decrease in prepaid deferred expense and other assets32 · Mar 2020 to Jun 2026
  • Interest income other32 · Mar 2020 to Jun 2026
  • Net cash provided by used in investing activities32 · Mar 2020 to Jun 2026
  • Net cash provided by used in operating activities32 · Mar 2020 to Jun 2026
  • Net income loss32 · Mar 2020 to Jun 2026
  • Operating expenses (US GAAP)32 · Mar 2020 to Jun 2026
  • Operating income loss32 · Mar 2020 to Jun 2026
  • Other nonoperating income32 · Mar 2020 to Jun 2026
  • Payments to acquire property plant and equipment32 · Mar 2020 to Jun 2026
  • Profit loss32 · Mar 2020 to Jun 2026
  • Research and development expense32 · Mar 2020 to Jun 2026
  • Share based compensation32 · Mar 2020 to Jun 2026
  • Stockholders equity (US GAAP)32 · Mar 2020 to Jun 2026
  • Net cash provided by used in financing activities30 · Sep 2020 to Jun 2026

Segment10 concepts · 107 facts · Dec 2023 to Jun 2026

  • Allocated share based compensation expense13 · Dec 2023 to Jun 2026
  • Depreciation nonproduction13 · Dec 2023 to Jun 2026
  • Net income loss13 · Dec 2023 to Jun 2026
  • Operating income loss13 · Dec 2023 to Jun 2026
  • Other labor related expenses13 · Dec 2023 to Jun 2026
  • Single reportable segment13 · Dec 2023 to Jun 2026
  • Interest income expense nonoperating net11 · Dec 2023 to Jun 2026
  • Other general expense10 · Dec 2023 to Mar 2026
  • Segment reporting other item amount5 · Dec 2023 to Jun 2026
  • Other nonoperating income3 · Dec 2023 to Dec 2025

Segments

107 facts

Figures broken down by business line, region, product or another axis the company reports on.

Statement business segments1 member · 107 facts

  • Single Reportable107 · Dec 2023 to Jun 2026

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

Transcripts with management claims and analyst questions, one per fiscal period.

No earnings-call transcripts for this company.

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.

Edgewise Therapeutics, Inc. (EWTX) data · FactIQ